The program has reached 81,413 students and 519 teachers across Georgia.

Atlanta, GA (August 5, 2024) – Georgia Bio’s Biotech Teacher Training Initiative (BTTI), formerly known as the Rural Teacher Training Initiative (RTTI), secured a significant increase in state funding in Georgia’s Fiscal Year 2025 budget. Total state funding now sits at $500,000. This investment from the state will be matched by industry donations in both cash and equipment, bringing the value of this program to $1+ million. Prior to receiving this increase in funding, the program conducted its fifth year of career-relevant instruction via hands-on teacher learning, impacting nearly 30,000 students and 150 teachers. In its first five years, the program has reached 81,413 students and 519 teachers across Georgia. Going forward, in conjunction with the additional funding and gifts from industry, BTTI will be able expand its operations in the urban areas of the state, impacting even more teachers and students.


This programmatic increase will support several initiatives, including hosting an additional cohort of teachers annually in an urban area where the density of industry sits, such as Atlanta or Augusta, and expanding the Equipment Depot and access to lab equipment. Plans for increased access include opening one satellite science equipment loaning office in Northwest Georgia, developing a shipment option with matching private funding, and potential for another satellite location in South Georgia. Further, funds will be allocated toward collaborating with Southwest Georgia RESA to provide teacher training for new science teachers in areas struggling to fill teacher positions, offer training and career path information for guidance counselors on opportunities in the life sciences, explore curriculum enhancement to include medical devices, and network with existing teachers.  

 

“Georgia Bio is the only organization in the State that offers this type of hands-on training program, complemented with classroom supplies and access to career pathway understanding,” said Maria Thacker-Goethe, President and CEO of Georgia Bio. “Investing in improving access to resources for educators can open life changing careers for students and be a boon to Georgia’s economy, and this increase in funding signifies that the State agrees. As the industry continues its rapid growth across the state, our companies need to know there is a workforce pipeline being developed and we help innovatively address that need. I am excited for the future of BTTI and grateful for the support of the State and members of our industry as we endeavor to build upon this program’s value and success.”


“With the explosive growth in biotechnology has come the heightened need for a qualified workforce,” says BTTI Instructor Stan Harrison, also Biotech Pathway Teacher at the Athens Community Career Academy and State Coordinator for the Biotechnician-Assistant Credentialing Exam (BACE). “We hear it echoed again and again that companies are struggling to hire and retain qualified production staff and therefore unable to manufacture high demand and often life-saving products. Quality training starts with highly trained secondary teachers who understand industry recognized standards. Georgia Bio’s BTTI provides a host of professional learning workshops and along with the Equipment Depot, a structured means to network and access cutting edge materials for modern lab training.”


BTTI is a public/private workforce development partnership between the life sciences sector and the State of Georgia. Led by Program Director, Megan Heaphy, BTTI offers hands-on, immersive science teacher professional development for Georgia teachers state-wide. Curriculum is built to highlight and leverage the biotechnology that exists within traditional science courses, including biology and AP biology, chemistry and AP chemistry, physics, environmental biology, agriculture and horticulture, physical science, and life science.


About Georgia Bio 

Georgia Bio (GaBio) is the state’s most impactful life sciences membership organization, advocating for the sector and its diverse innovation pipeline. For over 30 years, GaBio has served its members by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in biotechnology, pharmaceuticals, and medical technology. GaBio also works closely with universities, academic and research institutions, the investment community, and other critical partners that promote this vibrant sector. GaBio works to shape public policy, improve access to breakthrough technologies, educate lawmakers, provide member programs, strengthens the workforce pipeline, and advance equity within our ecosystem by championing innovative solutions for some of the most pressing challenges of our times. For more information, visit www.gabio.org. 

 

MEDIA CONTACT: 

Melissa Carter 

404-920-2043 

mcarter@gabio.org 

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: